NEW YORK – Immunomedics said on Wednesday that its antibody drug conjugate sacituzumab govitecan-hziy (Trodelvy) was approved by the US Food and Drug Administration for previously treated metastatic triple-negative breast cancer.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.